For example, within this broader group of neoplasms, fusions of PDGFRA and PDGFRB with a variety of gene partners (not including JAK2) have been reported to respond well to imatinib.20–24 The general approach to these fusion variants is discussed in the current National Comprehensive Cancer Network (NCCN) guidelines.8 This evidence concerns the gene JAK2 and neoplasm.